Daniel W. Muehl
2008 - Repligen
In 2008, Daniel W. Muehl earned a total compensation of $108.8K as Chief Financial Officer at Repligen, a 71% decrease compared to previous year.
Compensation breakdown
| Option Awards | $34,309 |
|---|---|
| Salary | $74,499 |
| Total | $108,808 |
Muehl received $74.5K in salary, accounting for 68% of the total pay in 2008.
Muehl also received $34.3K in option awards.
Rankings
In 2008, Daniel W. Muehl's compensation ranked 8,991st out of 9,135 executives tracked by ExecPay. In other words, Muehl earned more than 1.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,991 out of 9,135 | 2nd |
Division Manufacturing | 3,393 out of 3,436 | 1st |
Major group Chemicals And Allied Products | 803 out of 815 | 2nd |
Industry group Drugs | 587 out of 597 | 2nd |
Industry Biological Products, Except Diagnostic Substances | 115 out of 118 | 3rd |
Source: SEC filing on July 29, 2008.
Muehl's colleagues
We found four more compensation records of executives who worked with Daniel W. Muehl at Repligen in 2008.
News
Clovis Oncology CEO Patrick Mahaffy's 2021 pay slips 18% to $2.6M
April 27, 2022
Clovis Oncology CEO Patrick Mahaffy's 2020 pay falls 53% to $3.2M
April 28, 2021
Clovis Oncology CEO Patrick Mahaffy's 2019 pay rises 10% to $6.9M
April 24, 2020
Clovis Oncology CEO Patrick Mahaffy's 2018 pay falls 28% to $6.3M
April 26, 2019